Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 5/20 | 0.33 |
| ▸ | HRH1 | P35367 | 5/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 4/20 | 0.32 |
| ▸ | HTR1A | P08908 | 3/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18611442 | 0.91 | KDM1A (0.36) | KDM1AHTR7HTR1ADRD2HTR6 | |
| SCHEMBL20325149 | 0.84 | KDM1A (0.45) | KDM1AHRH2HRH1HRH3HTR7 | |
| SCHEMBL21215059 | 0.80 | KDM1A (0.41) | KDM1AHRH2HRH1HRH3HTR7 | |
| SCHEMBL18591812 | 0.79 | KCNH2 (0.38) | KDM1AHRH2HRH1HRH3HTR7 | |
| SCHEMBL23695901 | 0.79 | KDM1A (0.32) | KDM1AHRH2HRH1HRH3HTR7 | |
| SCHEMBL20463166 | 0.76 | KDM1A (0.49) | KDM1AHTR7HTR1ADRD2HTR6 | |
| SCHEMBL21025868 | 0.74 | CYP2D6 (0.40) | KDM1AHRH1HRH3HTR7HTR1A | |
| SCHEMBL24508477 | 0.73 | KDM1A (0.31) | KDM1AHTR7HTR1A | |
| SCHEMBL18591791 | 0.73 | GBA2 (0.34) | KDM1AHRH3HTR7HTR1A | |
| SCHEMBL24774552 | 0.71 | KDM4E (0.34) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | KDM1A 1754/4885HRH2 4040/4885HRH1 3498/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | KDM1A 1754/4885HRH2 4040/4885HRH1 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.